The early referral for reduced-intensity stem cell transplantation in patients with Ph1 (+) chronic myelogenous leukemia in chronic phase in the imatinib era: Results of the Latin American Cooperative Oncohematology Group (LACOHG) prospective, multicenter study

Bone Marrow Transplantation

Volumn 36, Issue 12, 2005, Pages 1043-1047

  Ruiz Arguelles G J ^a,b   Gomez Almaguer D ^c   Morales Toquero, A ^a   Gutierrez Aguirre C H ^c   Vela Ojeda, J ^d   Garcia Ruiz Esparza M A ^d   Manzano, C ^a   Karduss, A ^e   Sumoza, A ^f   de Souza, C ^g   Miranda, E ^g   Giralt, S ^h  

^a CENTRO DE HEMATOLOGÍA Y MEDICINA INTERNA DE PUEBLA   (Mexico)

^b Laboratorios Clinicos de Puebla   (Mexico)

^c HOSPITAL UNIVERSITARIO DR JOSÉ ELEUTERIO GONZÁLEZ   (Mexico)

^d INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

^e Section of Neuro oncology   (Colombia)

^f UNIVERSIDAD DE CARABOBO   (Venezuela)

^g UNIVERSITY OF CAMPINAS   (Brazil)

^h UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Allograft; Chronic; Leukemia; Myelogenous; Reduced intensity

Indexed keywords

ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; BUSULFAN; CD34 ANTIGEN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; HYDROXYUREA; IMATINIB; INTERFERON; METHOTREXATE; ONDANSETRON; PYRROLE DERIVATIVE; QUINOLONE;

ACUTE GRAFT VERSUS HOST DISEASE; ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; ALLOTRANSPLANTATION; ARTICLE; BRAZIL; CANCER PATIENT; CHRONIC GRAFT VERSUS HOST DISEASE; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CLINICAL TRIAL; COLOMBIA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ENTERITIS; FEMALE; GRANULOCYTE; HLA SYSTEM; HUMAN; LIVING DONOR; MALE; MEXICO; MORTALITY; MULTICENTER STUDY; PATIENT REFERRAL; PHILADELPHIA 1 CHROMOSOME; PRIORITY JOURNAL; PROBABILITY; PROSPECTIVE STUDY; REDUCED INTENSITY CONDITIONING; SCHOOL CHILD; SEPSIS; SIBLING; SOUTH AND CENTRAL AMERICA; STEM CELL TRANSPLANTATION; SURVIVAL RATE; THROMBOCYTE; VENEZUELA;

EID: 30544444396     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/sj.bmt.1705190     Document Type: Article

References (26)

1. Goldman JM. Treatment of chronic myeloid leukemia: Some topical questions. Bailliere's Clin Haematol 1997; 10: 405-420.
2. Gómez-Almaguer D. Leucemias crónicas. In: Ruiz-Argüelles GJ (ed.). Fundamentos de Hematologia, 3rd edn. Editorial Médica Panamericana: México City, 2004, pp 246-260.
3. Ruiz-Argüelles GJ, López-Martínez B, Ramírez-Cabrera JM et al. Molecular monitoring of the treatment of patients with BCR/ABL (+) chronic myelogenous leukemia. Rev Invest Clan Méx 2001; 53: 235-239.
4. Gómez-Almaguer D, Ruiz-Argüelles GJ, Ruiz-Argüelles A et al. Hematopoietic stem cell allografts using a non-myeloablative conditioning regimen can be safely performed on an outpatient basis. Bone Marrow Transplant 2000; 25: 131-133.
5. Ruiz-Argüelles GJ, Gómez-Almaguer D, Ruiz-Argüelles A et al. Results of an outpatient-based stem cell allotransplant program using non-myeloablative conditioning regimens. Am J Hematol 2001; 66: 241-244.
6. Ruiz-Argüelles GJ, Gómez-Almaguer D, López-Martínez B et al. Results of an allogeneic non-myeloablative stem cell transplantation program in patients with chronic myelogenous leukemia. Haematologica 2002; 87: 894-896.
7. Or R, Shapira MY, Resnick I et al. Nonmyeloablative allogeneic stem cell transplantation for the treatment of chronic myeloid leukemia in first chronic phase. Blood 2003; 101: 441-445.
8. Ruiz-Argüelles GJ. Foro Clínico: El efecto de injerto contra tumor en leucemia granulocítica crónica. Rev Invest Clín Mex 2002; 54: 154-160.
9. Ruiz-Argüelles GJ. Allogeneic stem cell transplantation using non-myeloablative conditioning regimens: Results of the Mexican approach. Int J Hematol 2002; 76 (Suppl. 1): 376-379.
10. Kessinger A, Armitage JO, Landmark JD et al. Autologous peripheral hematopoietic stem cell transplantation restores hemopoietic function following marrow ablative therapy. Blood 1998; 71: 723-727.
11. Giralt S, Estey E, Albitar M et al. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: Harnessing graft-versus-leukemia without myeoablative therapy. Blood 1997; 89: 4531-4536.
12. Slavin S, Nagler A, Naparstek E et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cyto-reduction for the treatment of malignant and nonmalignant hematological diseases. Blood 1998; 91: 756-763.
13. Ruiz-Argüelles A. Flow cytometry in the clinical laboratory. Principles, applications and problems. Ann Biol Clin 1992; 50: 735-743.
14. Ruiz-Argüelles A, Orfao A. Caracterización y evaluación de células totipotenciales en sangre periférica y médula ósea. In: Ruiz-Argüelles GJ, San-Miguel JF (eds). Actualización en Leucemias. Editorial Médica Panamericana: México City, 1996, pp 79-82.
15. Pinkel D, Straume T, Gray JW. Cytogenetic analysis using quantitative, high sensitivity fluorescence hybridization. Proc Natl Acad Sci USA 1996; 83: 2934-2938.
16. Yam P, Petz L, Knowlton R et al. Use of DNA restriction fragment length polymorphisms to document marrow engraftment and mixed hematopoietic chimerism following bone marrow transplantation. Transplantation 1987; 43: 399-407.
17. Ruiz-Argüelles GJ, Garcés-Eisele J, Reyes-Núñez V et al. Assessment of residual disease in acute leukemia by means of polymerase chain reaction: A prospective study in a single institution. Rev Invest Clin Mex 2000; 52: 118-124.
18. Hochhaus A, Berger U, Hehlmann R. Therapy of chronic myelogenous leukemia in 2004. Dtsch Med Wochenschr 2004; 129: 2122-2127.
19. Ruiz-Argüelles GJ, Gómez-Almaguer D. Breaking dogmata to help patients: Non-myeloablative hematopoietic stem cell transplantation. Expert Opin Biol Ther 2004; 4: 1693-1699.
20. Weisser M, Schleuning M, Ledderose G et al. Reduced-intensity conditioning using TBI (8 Gy), fludarabine, cyclophosphamide and ATG in elderly CML patients provides excellent results especially when performed in the early course of the disease. Bone Marrow Transplant 2004; 34: 1083-1088.
21. Okamoto S, Watanabe R, Takahashi S et al. Long-term follow-up of allogeneic bone marrow transplantation after reduced-intensity conditioning in patients with chronic myelogenous leukemia in the chronic phase. Int J Hematol 2002; 75: 493-498.
22. Basara N, Roemer E, Kraut L et al. Reduced intensity preparative regimens for allogeneic hematopoietic stem cell transplantation: A single center experience. Bone Marrow Transplant 2002; 30: 651-659.
23. Khoury H, Adkins D, Brown R et al. Low incidence of transplantation related acute complications in patients with chronic myeloid leukemia undergoing allogeneic stem cell transplantation with a low-dose (550 cGy) total body irradiation conditioning regimen. Biol Blood Marrow Transplant 2001; 7: 352-358.
24. Das M, Saikia TK, Advani SH et al. Use of a reduced-intensity conditioning regimen for allogeneic transplantation in patients with chronic myeloid leukemia. Bone Marrow Transplant 2003; 32: 125-129.
25. Baron F, Maris MB, Storer BE et al. HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with chronic myeloid leukemia. Biol Blood Marrow Transplant 2005; 11: 272-279.
26. Couriel DR, Saliba RM, Giralt S et al. Acute and chronic graft versus-host-disease after ablative and nonmyeloablative conditioning for allogeneic hematopoietic transplantation. Biol Blood Marrow Transplant 2004; 10: 178-185.